Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345404 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
A Phase 1 study of Atopic Dermatitis, sponsored by Corvus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 16
- Study locations
NCT06345404: Completed Phase 1 study of Atopic Dermatitis, sponsored by Corvus Pharmaceuticals.
NCT06345404 is a Phase 1 study of Atopic Dermatitis that has completed, run by Corvus Pharmaceuticals. The registered enrollment target is 82 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (87% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06345404, a Phase 1 study of Atopic Dermatitis, has completed, sponsored by Corvus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 16
- Study locations
Study Summary
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Primary Outcome
Incidence, nature, and severity of treatment-emergent adverse events of soquelitinib compared with placebo, including changes in laboratory values, vital signs, and electrocardiograms (ECGs)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Soquelitinib
Study Locations (16)
California
- Clinical Site 2 - Fremont
- Clinical Site 7 - Palo Alto
- Clinical Site 13 - Pomona
New York
- Clinical Site 11 - Brooklyn
- Clinical Site 16 - New York
- Clinical Site 12 - New York
Pennsylvania
- Clinical Site 1 - Camp Hill
- Clinical Site 8 - Philadelphia
Texas
- Clinical Site 4 - Frisco
- Clinical Site 14 - San Antonio
Alabama
- Clinical Site 5 - Birmingham
Arizona
- Clinical Site 9 - Tucson
Arkansas
- Clinical Site 3 - North Little Rock
Colorado
- Clinical Site 10 - Castle Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-04-16 |
| Est. Completion | 2026-02-24 |
| Phase | Phase 1 |
What the finished NCT06345404 record still lists
NCT06345404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06345404 lists 16 locations in 10 states (California, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06345404 about?
NCT06345404 is a clinical study titled "Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD". Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
What is the current status of trial NCT06345404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2024-04-16. Estimated completion is 2026-02-24.
What conditions does trial NCT06345404 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06345404?
The interventions under investigation include: Placebo (DRUG), Soquelitinib (DRUG).
Who is sponsoring clinical trial NCT06345404?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345404 being conducted?
This trial has 16 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06345404's enrollment target sits among peer trials
82 98th of 150 higher than 52 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 1
-
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
RECRUITING · Phase 1
-
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI